NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Orbimed Advisors Llc sold 14,069 shares of the stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.01, for a total transaction of $197,106.69. Following the transaction, the insider now directly owns 3,504,898 shares of the company’s stock, valued at approximately $49,103,620.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, April 18th, Orbimed Advisors Llc sold 2,623 shares of NeuroPace stock. The stock was sold at an average price of $14.06, for a total transaction of $36,879.38.
- On Thursday, April 11th, Orbimed Advisors Llc sold 461,899 shares of NeuroPace stock. The stock was sold at an average price of $14.49, for a total transaction of $6,692,916.51.
NeuroPace Stock Up 1.8 %
NASDAQ:NPCE traded up $0.25 during mid-day trading on Thursday, hitting $14.00. The stock had a trading volume of 65,350 shares, compared to its average volume of 106,465. The stock has a 50-day simple moving average of $14.59 and a two-hundred day simple moving average of $11.34. The company has a market capitalization of $367.92 million, a PE ratio of -10.94 and a beta of 2.08. NeuroPace, Inc. has a twelve month low of $3.80 and a twelve month high of $18.15. The company has a current ratio of 5.71, a quick ratio of 5.02 and a debt-to-equity ratio of 2.76.
Institutional Trading of NeuroPace
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. acquired a new stake in NeuroPace during the third quarter worth approximately $29,000. Virtu Financial LLC acquired a new stake in NeuroPace during the fourth quarter worth approximately $111,000. Barclays PLC raised its holdings in NeuroPace by 9,085.6% during the third quarter. Barclays PLC now owns 10,839 shares of the company’s stock worth $105,000 after purchasing an additional 10,721 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in NeuroPace during the second quarter worth approximately $63,000. Finally, Susquehanna International Group LLP acquired a new stake in NeuroPace during the first quarter worth approximately $65,000. Institutional investors and hedge funds own 78.83% of the company’s stock.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. Wells Fargo & Company raised shares of NeuroPace from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $16.00 to $20.00 in a research note on Thursday, March 14th. SVB Leerink initiated coverage on shares of NeuroPace in a research note on Tuesday, January 30th. They issued an “outperform” rating and a $22.00 price objective for the company. Cantor Fitzgerald raised their price objective on shares of NeuroPace from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Morgan Stanley raised their price objective on shares of NeuroPace from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 6th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of NeuroPace in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.67.
Read Our Latest Stock Analysis on NeuroPace
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Recommended Stories
- Five stocks we like better than NeuroPace
- The Role Economic Reports Play in a Successful Investment Strategy
- Comprehensive PepsiCo Stock Analysis
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- How to Calculate Stock Profit
- Bear Market Funds to Watch This Year
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.